Antengene today announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. Read more: antengene.com/newsinfo/411
关于我们
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Shanghai，Changning District
- 类型
- 上市公司
- 创立
- 2017
- 领域
- 抗肿瘤创新药物、新药开发和临床研究
地点
-
主要
获取路线
CN，Changning District，Shanghai，200000
Antengene员工
动态
-
Antengene today announced that the Thailand Food and Drug Administration has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications. Read more: antengene.com/newsinfo/407
Newsroom
antengene.com
-
Antengene today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The Company will share the latest advancements in R&D during a Fireside Chat. Read more：antengene.com/newsinfo/396
Newsroom
antengene.com
-
Antengene Corporation (6996.HK) today announced its interim results for the period ending June 30, 2024, along with several significant milestones achieved in recent months. Read more: antengene.com/newsinfo/395
Newsroom
antengene.com
-
Antengene today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications. Read more: antengene.com/newsinfo/393
Newsroom
antengene.com
-
Antengene today announced that the China National Medical Products Administration (NMPA) has approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Read more: https://lnkd.in/grPvUdcZ
Newsroom
antengene.com
-
Antengene today announced that South Korea’s National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). XPOVIO® will be officially included into the national reimbursed drugs list of South Korea on July 1, 2024. Read more: antengene.com/newsinfo/389
-
Antengene today announced its participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. The Company will share the differentiations and latest advancements of AnTenGager™, its proprietary “2+1” T Cell Engager Platform, during a Fireside Chat. Read more: antengene.com/newsinfo/388
Newsroom
antengene.com
-
Antengene today announced one oral presentation, three poster presentations and a journal publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL, the United States. Read more: antengene.com/newsinfo/387
-
-
Antengene today announced the presentation of four abstracts (including one oral presentation and three poster presentations) at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL, the United States. Read more：https://lnkd.in/g4nRtZHf
-